Apollo Hospitals

apollohospitals.com

Driven by the vision of its Chairman, Dr. Prathap C. Reddy, the Apollo Hospitals Group pioneered corporate healthcare in India. Over the last 25 years Apollo Hospitals has become the largest integrated private hospital group in Asia with expertise in managing hospitals, clinics, health insurance, healthcare IT, Telemedicine, Education, Pharmacy retail & Medical business process outsourcing. It owns & manages over 10000 beds across 51 hospitals, 1517 pharmacies & 102 clinics & holds the distinction of being the first amongst Indian hospitals to be accredited by Joint Commission International, USA. At present five Apollo hospitals at New Delhi, Bangalore, Chennai, Hyderabad & Dhaka are accredited by JCI. The group has always pioneered introduction of the latest world class technology in India at its hospitals like 320 Slice CT, Cyber-knife, & Computer Navigated Surgery.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET, PHARMA TECH

CAPSIDA BIOTHERAPEUTICS AND ABBVIE ANNOUNCE EXPANSION OF COLLABORATION

Capsida Biotherapeutics | February 27, 2023

news image

Capsida Biotherapeutics Inc., a fully integrated next-generation gene therapy platform company, and AbbVie, a pharmaceutical company dedicated to discovering and providing innovative medicines to address serious health issues, have recently announced an expanded strategic collaboration. The collaboration aims to develop genetic medicines for eye diseases with high unmet needs. Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability will...

Read More

Business Insights

ANGELINI PHARMA, A NEW PARTNER IN EPILEPSY

Angelini Pharma | March 26, 2022

news image

On the occasion of Purple Day an annual international event aimed at raising awareness of epilepsy, Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy. Epilepsy is a common neurological disorder that typically results in seizures of various types, with focal seizures being the most common one.1 The essential treatment goal of epilepsy the...

Read More

Business Insights

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

news image

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More

Business Insights

ELEMENT FURTHER EXPANDS ITS LIFE SCIENCES TESTING BUSINESS WITH ADDITIONAL PHARMACEUTICAL AND BIOTECH TESTING CAPABILITIES IN NORTH AMERICA AND EUROPE

Element Materials Technology | January 15, 2022

news image

Element Materials Technology (Element) completed its sixth life sciences-focused acquisition of 2021, with the formal completion of the acquisition of JMI Laboratories. Element has now built out its expertise and capability for pharmaceutical and biopharmaceutical customers, expanding to a team of more than 1,000 experts in 23 facilities across North America and Europe. This significant step change in pharmaceutical and medical testing capabilities from Element forms part of its b...

Read More
news image

PHARMACY MARKET, PHARMA TECH

CAPSIDA BIOTHERAPEUTICS AND ABBVIE ANNOUNCE EXPANSION OF COLLABORATION

Capsida Biotherapeutics | February 27, 2023

Capsida Biotherapeutics Inc., a fully integrated next-generation gene therapy platform company, and AbbVie, a pharmaceutical company dedicated to discovering and providing innovative medicines to address serious health issues, have recently announced an expanded strategic collaboration. The collaboration aims to develop genetic medicines for eye diseases with high unmet needs. Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability will...

Read More
news image

Business Insights

ANGELINI PHARMA, A NEW PARTNER IN EPILEPSY

Angelini Pharma | March 26, 2022

On the occasion of Purple Day an annual international event aimed at raising awareness of epilepsy, Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy. Epilepsy is a common neurological disorder that typically results in seizures of various types, with focal seizures being the most common one.1 The essential treatment goal of epilepsy the...

Read More
news image

Business Insights

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More
news image

Business Insights

ELEMENT FURTHER EXPANDS ITS LIFE SCIENCES TESTING BUSINESS WITH ADDITIONAL PHARMACEUTICAL AND BIOTECH TESTING CAPABILITIES IN NORTH AMERICA AND EUROPE

Element Materials Technology | January 15, 2022

Element Materials Technology (Element) completed its sixth life sciences-focused acquisition of 2021, with the formal completion of the acquisition of JMI Laboratories. Element has now built out its expertise and capability for pharmaceutical and biopharmaceutical customers, expanding to a team of more than 1,000 experts in 23 facilities across North America and Europe. This significant step change in pharmaceutical and medical testing capabilities from Element forms part of its b...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us